Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forma Therapeutics IncfiledCriticalForma Therapeutics Inc
Publication of MA46064ApublicationCriticalpatent/MA46064A/en
Publication of MA46064B1publicationCriticalpatent/MA46064B1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Plural Heterocyclic Compounds
(AREA)
Abstract
Cette invention concerne des inhibiteurs de protéines d'isocitrate déshydrogénase mutantes (mt-idh) ayant une activité néomorphe, utiles pour traiter les troubles liés à la prolifération cellulaire et les cancers, de formule : (i) où a, u, w1, w2, w3, r1-r6, et r9 sont tels que décrits dans la présente.This invention relates to mutant isocitrate dehydrogenase (mt-idh) protein inhibitors having neomorphic activity useful for treating cell proliferation-related disorders and cancers of the formula: (i) where a, u, w1, w2 , w3, r1-r6, and r9 are as described herein.
Compounds derived from 2- (ethynyl-pyridin-2-yl) -pyrazolidin-3-one, 2- (ethynyl-pyrimidin-2-yl) -pyrazolidin-3-one or 2- (ethynyl-pyridazin-3-yl) -pyrazzolidin-3-one; mglur5 positive allosteric modulators; preparation procedure; pharmaceutical composition; and its use to treat schizophrenia or cognitive diseases.